What Is a Personalized Cancer Vaccine? Tumor Lysate, Dendritic Cells, and the mRNA Approach
Summary: Personalized cancer vaccines are immunotherapy approaches that combine antigenic material (lysate) derived from the patient’s own tumor, genetic signature analysis (RNA-seq/mRNA neoantigens), and dendritic cells—the “teacher cells” of the immune system. To date, only Sipuleucel-T (Provenge) has received FDA approval in this category; other approaches (DCVax-L, mRNA-4157/V940, BioNTech personalized vaccines) are still in the clinical trial phase.
Why Aren’t Standard Treatments Always Sufficient?
Targeted therapies focus on a single mutation in the tumor (e.g., EGFR, BRAF). However, tumors are typically heterogeneous; that is, they contain different genetic subpopulations. Targeting a single target can lead to the emergence of treatment-resistant cells (clonal escape). The theoretical basis of the personalized multi-antigen approach is the idea of eliciting a broader immune response by presenting the tumor’s “complete identity” to the immune system.
The Three Components of the Approach
1. Tumor Lysate
The mixture obtained by breaking down tumor tissue collected via surgery or biopsy contains numerous tumor-specific antigens. This is based on the idea of eliciting an immune response not against a single protein, but against the tumor’s “complete protein profile.”
2. Dendritic Cell Training
Dendritic cells are the antigen-presenting cells of the immune system; they teach T cells “what to fight.” Dendritic cells are produced in a laboratory setting from leukocytes collected from the patient via apheresis and are “trained” by being cultured together with the tumor lysate.
3. RNA-seq and mRNA Neoantigens
RNA sequencing (RNA-seq) of tumor tissue identifies protein fragments (neoantigens) that are specific to cancer cells and not found in normal cells. Synthetic mRNAs corresponding to the sequences of these neoantigens can be produced and presented to the immune system—similar to the mRNA technology used in COVID-19 vaccines, but tailored to the individual.
Level of Scientific Evidence: Approved or in the Research Phase?
This is the point that potential patients find most confusing, so it’s important to be clear:
| Approach |
Status |
Cancer Type |
| Sipuleucel-T |
FDA approved (2010) |
Metastatic
castration-resistant prostate cancer |
| DCVax-L |
Phase
3 completed, regulatory review ongoing; no
FDA approval yet |
Glioblastoma |
| mRNA-4157
/ V940 (Moderna–Merck) |
Positive
Phase 2b results; Phase 3 (INTerpath program) ongoing |
High-risk
resected melanoma, NSCLC, and others |
| BioNTech
personalized neoantigen vaccines |
In
clinical trial phase |
Various
solid tumors |
| CIMAvax-EGF
(Cuba) |
In use
in some countries; different regulatory framework |
Advanced-stage
NSCLC |
This table has been prepared to help patients clearly understand the difference between “approved treatments” and “investigational approaches.” During the evaluation process, it must be clearly stated to the patient which category the approach in question falls into.
Who Is Eligible?
This approach is not a standalone treatment method but rather an option that can be considered in addition to existing treatments. The scientific evidence is quite robust, particularly for tumors with a high mutation burden (melanoma, NSCLC, bladder cancer) and in cases of minimal residual disease following surgery. Each patient’s eligibility must be assessed individually by a physician, taking into account tumor biology and overall health status.
Frequently Asked Questions
Does a personalized cancer vaccine replace chemotherapy?
No. This approach is generally not considered a replacement for existing treatments (chemotherapy, immunotherapy), but rather a combination strategy administered alongside or following these treatments.
Can these vaccines be administered to everyone?
No. Eligibility varies depending on tumor type, mutation burden, and the patient’s overall immune status; therefore, a personalized evaluation is required.
Is a guaranteed outcome provided?
No. This is an emerging field of treatment, and the response varies from patient to patient. No center can promise definite results.
This content is for informational purposes only; it does not diagnose, recommend treatment, or promise results. Be sure to consult a physician for a personalized evaluation.